National Quality Measures Clearinghouse | Measures by Topic: Prostatic Neoplasms

National Quality Measures Clearinghouse | Measures by Topic: Prostatic Neoplasms

September 2, 2013

Measures by Topic

Disease/Condition > Diseases (1455) > Neoplasms (181) > Neoplasms by Site (118) > Urogenital Neoplasms (11) > Genital Neoplasms, Male (5) >

Prostatic Neoplasms (5)

Search Within Search within:   Go

Sort results by:  Relevance (what's this?)    Publication date

Filter results by:

1-5 of 5
1.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling on, at a minimum, the following treatment options for clinically localized disease prior to initiation of treatment: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy. 2010 Sep. [NQMC Update Pending] NQMC:003487 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
2.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist). 2010 Sep. [NQMC Update Pending] NQMC:003488 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
3.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment. 2010 Sep. [NQMC Update Pending] NQMC:003484 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
4.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer. 2010 Sep. [NQMC Update Pending] NQMC:003486 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
5.   Prostate cancer: percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score. 2010 Sep. [NQMC Update Pending] NQMC:003485 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
1-5 of 5